List of Figures
Figure 1-1: Limitations of Conventional Drug Delivery Systems
Figure 1-2: Diversification of Novel Drug Delivery Platforms
Figure 1-3: History of Drug Delivery Technology from First Generation till Third Generation
Figure 1-4: Barriers to be Overcome by Third Generation Drug Delivery System
Figure 1-5: Demonstration of Targeted and Non-Targeted Drug Delivery
Figure 1-6: Controlled Drug Release by Zero Order Mechanism
Figure 1-7: Plasma Concentration v/s Time Profile in Conventional and Controlled Release
Figure 1-8: Comparison of Various Modified Drug Release Systems
Figure 1-9: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 1-10: Classification Based On Technicality Erudition
Figure 1-11: Structural Differentiation among Different Classified Drug Delivery Systems
Figure 1-12: Classification Based on Route of Administration
Figure 1-13: Differentiation of the Two Diffusion Controlled Mechanisms
Figure 1-14: Mechanism of Encapsulation Dissolution Controlled System
Figure 1-15: Osmotic Release of Drug with Controlled Mechanism
Figure 1-16: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 2-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 2-2: Various Nanostructures Available for Nanoparticulate Delivery System
Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2022
Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2023 - 2029
Figure 4-1: US -Controlled Release Market Size (US$ Billion), 2019 - 2029
Figure 4-2: US - Population Above and Below 65 Years of Age (%), 2022
Figure 4-3: Europe -Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2029
Figure 4-4: EU - Population Above and Below 65 Years (%), 2022
Figure 4-5: Japan - Population Above and Below 65 Years (%), 2022
Figure 4-6: China - Population Above and Below 65 Years (%), 2022
Figure 5-1: Global - Controlled Release Drug Clinical Pipeline by Company (Number), 2023 Till 2029
Figure 5-2: Global - Controlled Release Drug Clinical Pipeline by Country (Number), 2023 Till 2029
Figure 5-3: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2023 Till 2029
Figure 5-4: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2023 Till 2029
Figure 5-5: Global - Controlled Release Drug Clinical Pipeline by Patient Segment (Number), 2023 Till 2029
Figure 5-6: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2023 Till 2029
Figure 6-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 6-2: Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 6-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 9-1: Namzaric - Price of Oral Capsule, Extended Release of Different Dosages (US$), September’2023
Figure 9-2: Namenda XR - Available Dosage Strengths (mg)
Figure 9-3: Namenda XR - Price of 30 Oral Capsules, Extended Release of Dosages (US$), September’2023
Figure 9-4: Namenda XR - Price of 90 Extended-Release Oral Capsules of Dosage 14 mg, 28 mg (US$), September’2023
Figure 9-5: Razadyne ER - Available Dosage Strengths (mg)
Figure 9-6: Razadyne ER - Price of Oral Capsule, Extended Release of Dosage 8 mg, 16 mg, 24 mg (US$), September’2023
Figure 10-1: Gocovri XR - Available Dosage Strengths (mg)
Figure 10-2: Gocovri - Price of Extended Release Oral Capsules of Dosage 68.5 mg and 137 mg (US$), September’2023
Figure 10-3: Global - Gocovri Annual Sales (US$ Million), 2022-2023
Figure 10-4: Global - Gocovri Quarterly Sales (US$ Million), H1’2023
Figure 10-5: Global - Gocovri Quarterly Sales (US$ Million), 2022
Figure 10-6: Osmolex ER - Available Dosage Strengths (mg)
Figure 10-7: Osmolex ER - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 10-8: Mirapex ER - Available Dosage Strengths (mg)
Figure 10-9: Mirapex ER - Price of Oral Tablet, Extended Release (US$), September’2023
Figure 11-1: Perseris: Available Dosage Strengths (mg)
Figure 11-2: Perseris - Price of Subcutaneous Powder for Injection, Extended Release (US$) September’2023
Figure 11-3: Global - Perseris Annual Sales (US$ Millions), 2019-2022
Figure 11-4: Global - Perseris Quarterly Sales (US$ Millions), H1’2023
Figure 11-5: Global - Perseris Quarterly Sales (US$ Millions), 2022
Figure 11-6: Invega - Available Dosage Strengths (mg)
Figure 11-7: Invega - Price of Oral Tablets, Extended Release of Dosage 1.5 mg, 3 mg and 6mg (US$), September’2023
Figure 11-8: Invega - Price of Oral Tablets, Extended Release of Dosage 9 mg (US$), September’2023
Figure 11-9: Invega Sustenna - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-10: Invega Trinza - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-11: Invega Hafyera - Price of Extended Release Intramuscular Suspensions of Different Doses (US$), September’2023
Figure 11-12: Global - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-13: US - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-14: ROW - Invega Sustenna/Invega Trinza Annual Sales (US$ Million), 2019-2023*
Figure 11-15: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-16: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-17: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), H1’2023
Figure 11-18: Global - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-19: US - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-20: ROW - Invega Sustenna/ Invega Trinza Quarterly Sales (US$ Million), 2022
Figure 11-21: Seroquel XR - Available Dosage Strengths (mg)
Figure 11-22: Seroquel XR - Prices of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 11-23: Global - Seroquel XR Total Annual Sales (US$ Million), 2019 - 2021
Figure 11-24: Abilify Maintena - Available Dosage Strengths (mg)
Figure 11-25: Abilify Maintena - Price of Intramuscular Powder for Injection, Extended Release (US$), September’2023
Figure 11-26: Abilify Asimtufii - Price of Intramuscular Powder for Injection, Extended Release (US$), September’2023
Figure 11-27: Global - Abilify Maintena Annual Sales (US$ Million), 2019-2021
Figure 11-28: Global - Abilify Maintena Quarterly Sales (US$ Million), H1’2023
Figure 11-29: Global - Abilify Maintena Quarterly Sales (US$ Million), 2022
Figure 11-30: Aristada - Available Dosage Strengths (mg)
Figure 11-31: Aristada - Price of Intramuscular Suspension, Extended Release of Different Doses (US$), September’2023
Figure 11-32: Aristada Initio - Price of Intramuscular Suspension, Extended Release of Dose 675 mg/2.4 mL (US$), September’2023
Figure 11-33: Global - Aristada Annual Sales (US$ Million), 2019-2023*
Figure 11-34: Global - Aristada Quarterly Sales (US$ Million), H1’2023
Figure 11-35: Global - Aristada Quarterly Sales (US$ Million), 2022
Figure 11-36: Rykindo - Available Dosage Strengths (mg)
Figure 11-37: Uzedy - Available Dosage Strengths (mg)
Figure 11-38: Uzedy - Prices of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 12-1: Hysingla ER - Available Dosage Strengths (mg)
Figure 12-2: Hysingla ER - Price of Oral Tablet, Extended Release of Different Doses (US$), September’2023
Figure 12-3: Nucynta ER - Available Dosage Strengths (mg)
Figure 12-4: Nucynta ER - Price of Oral Tablets, Extended Release of Different Doses (US$), September’2023
Figure 12-5: Global - Nucynta ER Annual Sales (US$ Million), 2019-2023*
Figure 12-6: Global - Nucynta ER Quarterly Sales (US$ Million), H1’2023
Figure 12-7: Global - Nucynta ER Quarterly Sales (US$ Million), 2022
Figure 12-8: Kadian - Available Dosage Strengths (mg)
Figure 12-9: Kadian - Price of Oral Capsules, Extended Release of Dosage 10 mg/12 hr (US$), September’2023
Figure 12-10: Kadian - Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr and 10 mg/24 hr (US$), September’2023
Figure 12-11: Kadian - Price of Oral Capsules, Extended Release of Dosage 20 mg/12 hr (US$), September’2023
Figure 12-12: Kadian - Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr and 20 mg/24 hr (US$), September’2023
Figure 12-13: Kadian - Price of Oral Capsules, Extended Release of Dosage 30 mg/12 hr (US$), September’2023
Figure 12-14: Kadian - Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr and 30 mg/24 hr (US$), September’2023
Figure 12-15: Kadian - Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr and 40 mg/24 hr (US$), September’2023
Figure 12-16: Kadian - Price of Oral Capsules, Extended Release of Dosage 50 mg/12 hr (US$), September’2023
Figure 12-17: Kadian - Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr and 50 mg/24 hr (US$), September’2023
Figure 12-18: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/12 hr (US$), September’2023
Figure 12-19: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), September’2023
Figure 12-20: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/24 hr (US$), September’2023
Figure 12-21: Kadian - Price of Oral Capsules, Extended Release of Dosage 70 mg/12 to 24 hr (US$), September’2023
Figure 12-22: Kadian - Price of Oral Capsules, Extended Release of Dosage 80 mg/12 hr, 80 mg/12 to 24 hr and 80 mg/24 hr (US$), September’2023
Figure 12-23: Kadian - Price of Oral Capsules, Extended Release of Dosage 100 mg/12 hr, 100 mg/12 to 24 hr and 100 mg/24 hr (US$), September’2023
Figure 12-24: Kadian - Price of Oral Capsules, Extended Release of Dosage 130 mg/12 to 24 hr and 150 mg/12 to 24 hr (US$), September’2023
Figure 12-25: Kadian - Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr and 200 mg/24 hr (US$), September’2023
Figure 12-26: Xtampza ER - Available Dosage Strengths (mg)
Figure 12-27: Xtampza ER - Price of Oral Capsules, Extended Release of Different Doses (US$), September’2023
Figure 12-28: Global - Xtampza ER Annual Sales (US$ Million), 2019-2023*
Figure 12-29: Global - Xtampza ER Quarterly Sales (US$ Million), H1’2023
Figure 12-30: Global - Xtampza ER Quarterly Sales (US$ Million), 2022
Figure 12-31: MS Contin - Available Dosage Strengths (mg)
Figure 12-32: MS Contin - Price of Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), September’2023
Figure 12-33: Embeda - Price of Oral Capsules, Extended Release of Different Doses (US$), September’2023
Figure 13-1: Ampyra - Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), September’2023
Figure 13-2: Ampyra/ Fampyra - Global Annual Sales (US$ Million), 2019-2023*
Figure 13-3: Ampyra/ Fampyra - Global Quarterly Sales (US$ Million), H1’2023
Figure 13-4: Ampyra/ Fampyra - Global Quarterly Sales (US$ Million), 2022
Figure 13-5: Tecfidera - Available Dosage Strengths (mg)
Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), September’2023
Figure 13-7: Global - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-8: US - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-9: ROW - Tecdifera Annual Sales (US$ Million), 2019-2023*
Figure 13-10: Global - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-11: US - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-12: ROW - Tecdifera Quarterly Sales (US$ Million), H1’2023
Figure 13-13: Global - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-14: US - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-15: ROW - Tecdifera Quarterly Sales (US$ Million), 2022
Figure 13-16: Rayos - Available Dosage Strengths (mg)
Figure 13-17: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US$), September’2023
Figure 13-18: US - Rayos Annual Sales (US$ Million), 2019-2023*
Figure 13-19: Global - Rayos Quarterly Sales (US$ Million), H1’2023
Figure 13-20: Global - Rayos Quarterly Sales (US$ Million), 2022
Figure 13-21: Vumerity - Price of Oral Capsule, Delayed Release (US$), September’2023
Figure 13-22: Global - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-23: US - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-24: ROW - Vumerity Annual Sales (US$ Million), 2019-2023*
Figure 13-25: Global - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-26: US - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-27: ROW - Vumerity Quarterly Sales (US$ Million), H1’2023
Figure 13-28: Global - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-29: US - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-30: ROW - Vumerity Quarterly Sales (US$ Million), 2022
Figure 13-31: Bafiertam - Price of Oral Capsule, Delayed Release (US$), September’2023
Figure 14-1: Glumetza - Available Dosage Strengths (mg)
Figure 14-2: Glumetza - Price of Oral Tablets, Extended Release of Dosage 500 mg (US$), September’2023
Figure 14-3: Glumetza - Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), September’2023
Figure 14-4: Glucotrol XL - Available Dosage Strengths (mg)
Figure 14-5: Glucotrol XL - Price Oral Tablets Extended Release of Dosage 2.5 mg (US$), September’2023
Figure 14-6: Glucotrol XL - Price of Oral Tablets Extended Release of Dosages 5 mg and 10 mg (US$), September’2023
Figure 14-7: Glucotrol XL - Price of Oral Tablets Extended Release of Dosage 5 mg (US$), September’2023
Figure 14-8: Glucophage XR - Available Dosage Strengths (mg)
Figure 14-9: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 500 mg (US$), September’2023
Figure 14-10: Glucophage XR - Price of Oral Tablet, Extended Release of Dosage 750 mg (US$), September’2023
Figure 14-11: Bydureon - Price of Powder for Injection of Dosage 2 mg (US$), September’2023
Figure 14-12: Global - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-13: US - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-14: EU - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-15: ROW - Bydureon Annual Sales (US$ Million), 2019-2023
Figure 14-16: Global - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-17: US - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-18: EU - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-19: ROW - Bydureon Quarterly Sales (US$ Million), H1’2023
Figure 14-20: Global - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-21: US - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-22: EU - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-23: ROW - Bydureon Quarterly Sales (US$ Million), 2022
Figure 14-24: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 10 mg-5 mg-1000 mg and 25 mg-5 mg-1000 mg (US$), September’2023
Figure 14-25: Trijardy XR - Price of Oral Tablet, Extended Release of Dosage 12.5 mg-2.5 mg-1000 mg and 5 mg-2.5 mg-1000 mg (US$), September’2023
Figure 15-1: Procardia XL - Available Dosage Strengths (mg)
Figure 15-2: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 30 mg (US$), September’2023
Figure 15-3: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), September’2023
Figure 15-4: Procardia XL - Price of Oral Tablet, Extended Release of Dosage 90 mg (US$), September’2023
Figure 15-5: Toprol XL - Available Dosage Strengths
Figure 15-6: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 25 mg and 50 mg (US$), September’2023
Figure 15-7: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), September’2023
Figure 15-8: Toprol XL - Price of Oral Tablet, Extended Release of Dosage 200 mg (US$), September’2023
Figure 15-9: Global - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-10: US - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-11: EU - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-12: ROW - Toprol XL Annual Sales (US$ Million), 2019-2023
Figure 15-13: Global - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-14: US - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-15: EU - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-16: ROW - Toprol XL Quarterly Sales (US$ Million), H1’2023
Figure 15-17: Global - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-18: EU - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-19: ROW - Toprol XL Quarterly Sales (US$ Million), 2022
Figure 15-20: Adalat CC - Available Dosage Strengths (mg)
Figure 15-21: Adalat CC - Price of Oral Tablet Extended Release of Dosage 30 mg (US$), September’2023
Figure 15-22: Adalat CC - Price of Oral Tablet Extended Release of Dosage 60 mg (US$), September’2023
Figure 15-23: Adalat CC - Price of Oral Tablet Extended Release of Dosage 90 mg (US$), September’2023
Figure 15-24: Verelan PM - Available Dosage Strengths (mg)
Figure 15-25: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), September’2023
Figure 15-26: Verelan PM - Price of Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), September’2023
Figure 15-27: Cardizem LA - Available Dosage Strengths (mg)
Figure 15-28: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), September’2023
Figure 15-29: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), September’2023
Figure 15-30: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), September’2023
Figure 15-31: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), September’2023
Figure 15-32: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), September’2023
Figure 15-33: Cardizem LA - Price of Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), September’2023
Figure 16-1: Zynrelef - Price of Injectable Solution, Extended Release of Different Dosages (US$), September’2023
Figure 16-2: Global - Zynrelef Annual Sales (US$ Million), 2021-2023
Figure 16-3: Global - Zynrelef Quarterly Sales (US$ Million), H1’2023
Figure 16-4: Global - Zynrelef Quarterly Sales (US$ Million), 2022
Figure 17-1: Apretude - Price of Intramuscular Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 17-2: Cabenuva - Price of injectable Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 17-3: Rukobia - Price of injectable Suspension, Extended Release of Different Dosages (US$), September’2023
Figure 18-1: Qelbree - Available Dosage Strengths (mg)
Figure 18-2: Qelbree - Price of Oral Tablet, Extended Release of Dosages 100 mg and 150 mg (US$), September’2023
Figure 18-3: Qelbree - Price of Oral Tablet, Extended Release of Dosage 200 mg (US$), September’2023
Figure 18-4: Global - Qelbree Annual Sales (US$ Million), 2021-2023
Figure 18-5: Global - Qelbree Quarterly Sales (US$ Million), H1’2023
Figure 18-6: Global - Qelbree Quarterly Sales (US$ Million), 2022
Figure 18-7: Jornay PM - Available Dosage Strengths (mg)
Figure 18-8: Jornay PM - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-9: Cotempla XR-ODT - Available Dosage Strengths (mg)
Figure 18-10: Cotempla XR-ODT - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-11: Adzenys XR-ODT - Available Dosage Strengths (mg)
Figure 18-12: Adzenys XR-ODT - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 18-13: Global - Adzenys XR-ODT and Cotempla XR-ODT Annual Sales (US$ Million), 2021-2023
Figure 18-14: Global - Adzenys XR-ODT and Cotempla XR-ODT Quarterly Sales (US$ Million), H1’2023
Figure 18-15: Global - Adzenys XR-ODT and Cotempla XR-ODTQuarterly Sales (US$ Million), 2022
Figure 19-1: Rinvoq - Available Dosage Strengths (mg)
Figure 19-2: Rinvoq - Price of Oral Capsule, Extended Release of Doses 15 mg and 30 mg (US$), September’2023
Figure 19-3: Rinvoq - Price of Oral Capsule, Extended Release of Doses 45 mg (US$), September’2023
Figure 19-4: Global - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-5: US - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-6: ROW - Rinvoq Annual Sales (US$ Million), 2019-2023*
Figure 19-7: Global - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-8: US - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-9: ROW - Rinvoq Quarterly Sales (US$ Million), H1’2023
Figure 19-10: Global - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-11: US - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-12: ROW - Rinvoq Quarterly Sales (US$ Million), 2022
Figure 19-13: Ortikos - Available Dosage Strengths (mg)
Figure 19-14: Ortikos - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 19-15: Xeljanz XR - Available Dosage Strengths (mg)
Figure 19-16: Xeljanz XR - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 19-17: Global - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-18: US - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-19: EU - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-20: ROW - Xeljanz XR Annual Sales (US$ Million), 2019-2023
Figure 19-21: Global - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-22: US - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-23: EU - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), H1’2023
Figure 19-25: Global - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-26: US - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-27: EU - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 19-28: ROW - Xeljanz XR Quarterly Sales (US$ Million), 2022
Figure 20-1: Aemcolo - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 20-2: Talicia - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 21-1: Sublocade - Price of Subcutaneous Solution, Extended Release (US$), September’2023
Figure 21-2: Global - Sublocade Annual Sales (US$ Million), 2019-2023*
Figure 21-3: Global - Sublocade Quarterly Sales (US$ Million), H1’2023
Figure 21-4: Global - Sublocade Quarterly Sales (US$ Million), 2022
Figure 22-1: Astagraf XL - Available Dosage Strengths (mg)
Figure 22-2: Astagraf XL - Price of Oral Capsule, Extended Release (US$), September’2023
Figure 22-3: Envarsus XR - Available Dosage Strengths (mg)
Figure 22-4: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 0.75 mg (US$), September’2023
Figure 22-5: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 1 mg (US$), September’2023
Figure 22-6: Envarsus XR - Price of Oral Capsule, Extended Release of Dosage 4 mg (US$), September’2023
Figure 23-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 23-2: Major Challenges Faced by Controlled Drug Delivery System
